Celcuity (NASDAQ:CELC) Earns Buy Rating from Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Celcuity (NASDAQ:CELC) in a research note published on Friday,Benzinga reports. The brokerage currently has a $23.00 price objective on the stock.

A number of other equities analysts have also weighed in on CELC. Stifel Nicolaus increased their target price on shares of Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a research report on Monday, October 7th. Leerink Partners started coverage on shares of Celcuity in a research note on Monday, July 22nd. They issued an “outperform” rating and a $29.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price target on shares of Celcuity in a report on Thursday, August 15th. Leerink Partnrs upgraded Celcuity to a “strong-buy” rating in a research report on Monday, July 22nd. Finally, Lifesci Capital began coverage on Celcuity in a research note on Monday, August 26th. They issued an “outperform” rating and a $27.00 target price for the company. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $29.17.

Celcuity Stock Down 10.3 %

Shares of NASDAQ CELC opened at $12.66 on Friday. The company has a debt-to-equity ratio of 0.54, a current ratio of 14.95 and a quick ratio of 14.95. The stock has a market capitalization of $468.80 million, a PE ratio of -4.85 and a beta of 0.76. Celcuity has a one year low of $11.51 and a one year high of $22.19. The business’s fifty day moving average price is $15.15 and its 200-day moving average price is $16.04.

Institutional Trading of Celcuity

Large investors have recently modified their holdings of the business. Baker BROS. Advisors LP raised its stake in Celcuity by 189.9% in the first quarter. Baker BROS. Advisors LP now owns 1,552,478 shares of the company’s stock valued at $33,534,000 after purchasing an additional 1,017,000 shares in the last quarter. Samlyn Capital LLC lifted its holdings in shares of Celcuity by 92.4% during the 2nd quarter. Samlyn Capital LLC now owns 1,326,953 shares of the company’s stock worth $21,735,000 after acquiring an additional 637,190 shares during the last quarter. State Street Corp lifted its holdings in shares of Celcuity by 152.2% during the 3rd quarter. State Street Corp now owns 1,107,415 shares of the company’s stock worth $16,512,000 after acquiring an additional 668,318 shares during the last quarter. Braidwell LP lifted its stake in Celcuity by 71.2% during the third quarter. Braidwell LP now owns 884,306 shares of the company’s stock worth $13,185,000 after purchasing an additional 367,663 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Celcuity by 1.0% during the first quarter. Vanguard Group Inc. now owns 828,597 shares of the company’s stock worth $17,898,000 after purchasing an additional 7,821 shares during the last quarter. Institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.